Following the U.S. Supreme Court's decision in Wyeth v. Levine that FDA approval does not preempt state tort liability for drug makers, state court decisions like this one will be an important battle
ground in pharmaceutical companies» product liability litigation.
Not exact matches
It is hard to believe, for example, that Canada could not
in the end find common
ground with the US on some extension of patent protection for
pharmaceuticals, since it was able to do so
in the just - completed negotiations with the EU, or that an extension of the term of copyright protection from 50 to 70 years from the agreed baseline would have much if any real practical impact on Canada although it would be seen as a gain by the US given the heavy copyright portfolios of US entertainment
companies, allowing them an additional period of time to exploit their copyrighted content.
The reason computational biology never fully got off the
ground before now, he says, is that
pharmaceutical companies weren't yet grappling with the kinds of problems that are best - suited to computational biologists: finding useful signals
in tremendously large sets of unsorted, noisy data.
The Supreme Court of the United States further lay the
ground for this question
in 2011
in William H. Sorrell, Attorney General of Vermont, et al., with a regulatory case involving the prohibition of sale of patient information by doctors to
pharmaceutical companies for the purposes of data mining.